BioAtla, Inc. (BCAB) Stock Analysis

BioAtla, Inc. (BCAB) Healthcare & Pipeline Overview

BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in conditionally active biologic (CAB) antibody-drug conjugates for solid tumor cancers. Their pipeline includes BA3011, BA3021, and BA3071, targeting cancers such as NSCLC, melanoma, and ovarian cancer, positioning them within the competitive oncology therapeutics market.

What Is the Investment Thesis for BCAB?

BioAtla presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The company's CAB technology offers a potentially differentiated approach to cancer therapy, with the goal of reducing systemic toxicity. Key value drivers include the clinical progress of BA3011, BA3021, and BA3071, particularly in pivotal trials. Successful clinical trial outcomes and potential regulatory approvals could significantly increase the company's valuation. The company's high gross margin of 100.0% suggests strong potential profitability if products reach commercialization. However, the company's negative profit margin of -2980.3% reflects substantial ongoing R&D expenses. Investors should closely monitor clinical trial data, regulatory milestones, and the company's cash runway.

Based on FMP financials and quantitative analysis

BCAB Key Highlights

Market capitalization of $2.88M, reflecting its position as a small-cap biopharmaceutical company.

• Gross margin of 100.0%, indicating efficient cost management in product manufacturing.
• Profit margin of -2980.3%, highlighting significant ongoing research and development expenses typical of clinical-stage companies.
• Lead product candidate BA3011 targets multiple solid tumor types, including soft tissue sarcoma and NSCLC.
• Beta of 1.21, suggesting higher volatility compared to the overall market.

Who Are BCAB's Competitors?

BCAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BCAB's Key Strengths?

Novel CAB technology platform.

• Targeted approach to cancer therapy.
• Experienced management team.
• Strong intellectual property position.

What Are BCAB's Weaknesses?

Clinical-stage company with no approved products.

• High R&D expenses and negative profit margin.
• Reliance on clinical trial success.
• Limited financial resources.

What Could Drive BCAB Stock Higher?

BCAB catalyst: Data readouts from ongoing clinical trials of BA3011 in soft tissue sarcoma and NSCLC (projected Q4 2026).

• Initiation of Phase 3 trials for BA3011 pending positive Phase 2 results (projected H1 2027).
• Advancement of BA3021 and BA3071 through Phase 1/2 clinical trials.
• Potential for new strategic partnerships and collaborations.

What Are the Key Risks for BCAB?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Competition from established pharmaceutical companies with more resources.
• Regulatory hurdles and delays in obtaining approvals.
• High R&D expenses and cash burn rate.
• Dependence on successful development and commercialization of its product candidates.

What Are the Growth Opportunities for BCAB?

• Expansion of BA3011 into additional indications: BioAtla has the opportunity to expand the use of BA3011 beyond its current targets of soft tissue sarcoma, NSCLC, and ovarian cancer. Exploring its efficacy in other solid tumors could significantly increase its market potential. The global market for soft tissue sarcoma treatment is projected to reach $1.5 billion by 2028, while the NSCLC market is expected to exceed $30 billion. Timeline: Ongoing clinical trials with potential data readouts in the next 12-24 months.
• Advancement of BA3021 and BA3071 through clinical trials: The successful development and commercialization of BA3021 and BA3071 represent significant growth opportunities. BA3021 targets multiple solid tumor types, including melanoma, while BA3071 is a CAB anti-CTLA-4 antibody. The global market for melanoma treatment is projected to reach $10 billion by 2027. Timeline: Phase 1/2 trials ongoing with potential for Phase 3 initiation in 2027-2028.
• Strategic partnerships and collaborations: BioAtla can leverage strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and global distribution networks. The value of oncology-focused partnerships can range from upfront payments of $50 million to potential milestone payments exceeding $1 billion. Timeline: Ongoing discussions with potential partners, with potential deals announced in the next 12-18 months.
• Expansion into new therapeutic areas: While currently focused on oncology, BioAtla's CAB technology could be applied to other therapeutic areas, such as autoimmune diseases or inflammatory conditions. Exploring these new applications could diversify the company's pipeline and reduce its reliance on oncology. The global market for autoimmune disease treatments is projected to reach $150 billion by 2028. Timeline: Preclinical research ongoing with potential for new program initiation in 2027-2028.
• Geographic expansion into international markets: BioAtla can expand its commercial reach by entering international markets, particularly in Europe and Asia. These markets offer significant growth potential, driven by increasing healthcare spending and aging populations. The oncology market in Asia is projected to grow at a CAGR of 10% over the next five years. Timeline: Potential for initial market entry in Europe and Asia within the next 3-5 years, pending regulatory approvals.

What Are BCAB's Competitive Advantages?

• Proprietary Conditionally Active Biologics (CAB) technology platform.
• Strong intellectual property portfolio protecting its CABs and ADCs.
• Clinical-stage pipeline with multiple product candidates in development.
• Experienced management team with expertise in antibody engineering and oncology.

What Does BCAB Do?

BioAtla, Inc., founded in 2007 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's core technology centers around Conditionally Active Biologics (CABs), which are designed to be active in the tumor microenvironment while minimizing off-target effects on healthy tissues. BioAtla's lead product candidate, BA3011, is a CAB antibody-drug conjugate (ADC) targeting soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. In addition to BA3011, BioAtla is developing BA3021, a CAB ADC targeting multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer. The company is also advancing BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla's pipeline reflects its commitment to addressing unmet needs in oncology by developing targeted therapies with improved safety profiles.

What Products and Services Does BCAB Offer?

• Develops Conditionally Active Biologics (CABs) for cancer treatment.
• Creates antibody-drug conjugates (ADCs) targeting solid tumors.
• Designs therapies that are active in the tumor microenvironment.
• Minimizes off-target effects on healthy tissues.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Focuses on specific and selective antibody-based therapeutics.

How Does BCAB Make Money?

• Develops and patents novel CAB-based therapeutics.
• Out-licenses or co-develops its product candidates with pharmaceutical partners.
• Generates revenue through milestone payments and royalties on product sales.
• Funds research and development through venture capital and public offerings.

What Industry Does BCAB Operate In?

BioAtla operates within the competitive biotechnology industry, specifically focusing on oncology therapeutics. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in personalized medicine. The company's CAB technology positions it within the targeted therapy segment, competing with other companies developing antibody-drug conjugates and immunotherapies. The industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Success hinges on demonstrating clinical efficacy and safety, securing regulatory approvals, and establishing commercial partnerships.

Who Are BCAB's Key Customers?

• Patients with solid tumor cancers, including NSCLC, melanoma, and ovarian cancer.
• Pharmaceutical companies seeking to expand their oncology portfolios.
• Healthcare providers who prescribe cancer therapies.

Company Profile

BioAtla, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Jay Short. BCAB has traded publicly since 2020.

BioAtla, Inc. Financial Trajectory

BioAtla, Inc. (BCAB) reported $6.5M in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded net income of $452K, with diluted EPS of $0.27. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BCAB averaged $-6.42 in diluted EPS.

How BioAtla, Inc. Is Valued

BioAtla, Inc. carries a market capitalization of $2.88M, placing it in the micro-cap category.

Return on equity for BioAtla, Inc. stands at 166.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.

BioAtla, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

BioAtla, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 2546.5% below estimates on average.

Over the past six months, BioAtla, Inc. insiders filed 6 SEC Form 4 transactions — 6 sales and 0 purchases. On net that is roughly 939 shares disposed (about $3K), a signal worth weighing alongside the fundamentals.

BCAB Financials

BCAB Latest News

Common Questions About BCAB (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources